|
Pharmaceutical Products-Open-House Pharmaceutical Discount Contracts In Accordance With Section 130A (8C) Sgb V Trastuzumab, Atc L01fd01-Contract Regions Of Lower Saxony, Bremen And Saxony-Anhalt. It Is Not An Open Procedure, But A So-Called Open-House Model. The Form For The Open Procedure Is Only Used Because There Is No Form For The Open House Model. Contracts That Are Concluded In The Open House Model Are Not Subject To Procurement Law Due To A Lack Of Selection Decision. A Submission Under Public Procurement Regulations Is Not Connected To The Use Of This Form. The Aok Lower Saxony. The Health Insurance Fund, Acting As A Regional Association, The Aok Bremen/Bremerhaven, Acting As A State Association, The Aok Saxony-Anhalt-The Health Insurance Company, Acting As A State Association, The Bkk Landesverband Mitte, The Ikk Classic, Acting As A Regional Association For The Lower Saxony Contract Region, The Ikk Gesund Plus, Trading As A Regional Association For The Bremen And Saxony-Anhalt Regions Agriculture, Forsten And Gartenbau (Svlfg) As An Agricultural Health Insurance Company (Lkk), Acting As The Regional Association, The Knappschaft Region Directions North (Hamburg) And Cottbus -Berlin Represented By The Headquarters In Bochum, Trading As A State Association As Well As The Replacement Health Insurance Companies, The Technician Health Insurance (Tk), The Barmer, The Dak - Health Insurance - Kkh, The Handelskrankenkasse, The Handelskrankenkasse (Hkk), Bremen, The Hek - Hanseatic Health Insurance, Intend, With All Interested Pharmaceutical Companies Not Exclusive Discount Agreements On The Active Ingredient Trastuzumab, Atc L01fd01, According To § 130A Paragraph 8C Sgb V For Parenteral Preparations From Ready -Made Medicine In Oncology For Direct Medical Use In Patients Regions Lower Saxony, Bremen And Saxony-Anhalt. The Non-Exclusive Discount Agreements Are Each Offered For Regional Allos 1 (Lower Saxony /Bremen) And The Regionallos 2 (Saxony-Anhalt). The Aok Lower Saxony. The Health Fund. Is Authorized At The End Of These Discount Agreements, To The Termination And Other Actions Necessary Within The Framework Of The Open House Procedure. The Clients Offer All Interested Pharmaceutical Companies That Meet The Equivalent Requirements Below, The Conclusion Of Identical And Not Individually Negotiable Discount Agreements. The Earliest Possible Contract Is 01.07.2025, All Contracts End On June 30, 2027. The Offer Must Be Available At The Start Of The Contract On July 1St, 2025 By May 9, 2025. For A Later Start Of The Contract, The Offer Of The 21St Of The Respective Month For The Start Of The Contract Is Considered To Be The First Month Above (Example: Start Of The Contract 01.08.2025; Deadline To Submit The Offer: 21.06.2025). A Contract Is Concluded During This Term At Any Time, But At The Latest On April 21, 2027. The Contracts Can Be Terminated With A Period Of Eight Weeks At The End Of The Month. When Entering Into Force One Through Nationwide Or
|
